<DOC>
	<DOC>NCT00683046</DOC>
	<brief_summary>Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-cell depletion, in patients with hematologic malignancies undergoing non-myelo-ablative stem cell transplantation. 3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.</brief_summary>
	<brief_title>T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Zubrod performance status 2 (See Appendix B). Life expectancy is not severely limited by concomitant illness. Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol. Serum creatinine &lt;1.5 mg/dL or Creatinine Clearance &gt;50 ml/min . Serum bilirubin 2.0 mg/dl, SGPT &lt;3 x upper limit of normal No evidence of chronic active hepatitis or cirrhosis. HIVnegative Patient is not pregnant Patient or guardian able to sign informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Relapsed or refractory acute myelogenous or lymphoid leukemia.</keyword>
	<keyword>Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.Chronic myelogenous leukemia in accelerated phase or blast-crisis.</keyword>
	<keyword>Chronic myelogenous leukemia in chronic phase</keyword>
	<keyword>Chronic myelogenous leukemia in accelerated phase or blast-crisis</keyword>
	<keyword>Recurrent or refractory malignant lymphoma or Hodgkin's disease.</keyword>
	<keyword>Chronic lymphocytic leukemia, relapsed or with poor prognostic features.</keyword>
	<keyword>Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.</keyword>
	<keyword>Severe aplastic anemia after failure of immunosuppressive therapy.</keyword>
	<keyword>Myelodysplastic syndromes (including PNH)</keyword>
	<keyword>Multiple myeloma at high risk for disease recurrence.</keyword>
</DOC>